PE20241994A1 - Proteina mutante de interleucina-2 y fusion de la misma - Google Patents
Proteina mutante de interleucina-2 y fusion de la mismaInfo
- Publication number
- PE20241994A1 PE20241994A1 PE2024000528A PE2024000528A PE20241994A1 PE 20241994 A1 PE20241994 A1 PE 20241994A1 PE 2024000528 A PE2024000528 A PE 2024000528A PE 2024000528 A PE2024000528 A PE 2024000528A PE 20241994 A1 PE20241994 A1 PE 20241994A1
- Authority
- PE
- Peru
- Prior art keywords
- mutant protein
- fusion
- immunoconjugate
- dimer
- interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111110032 | 2021-09-22 | ||
| PCT/CN2022/120265 WO2023045977A1 (zh) | 2021-09-22 | 2022-09-21 | 白介素2突变体以及其融合蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241994A1 true PE20241994A1 (es) | 2024-09-27 |
Family
ID=85720093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000528A PE20241994A1 (es) | 2021-09-22 | 2022-09-21 | Proteina mutante de interleucina-2 y fusion de la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240391973A1 (https=) |
| EP (1) | EP4406965A4 (https=) |
| JP (1) | JP2024534545A (https=) |
| KR (1) | KR20240082364A (https=) |
| CN (1) | CN118119635A (https=) |
| AU (2) | AU2022350407B2 (https=) |
| CA (1) | CA3233075A1 (https=) |
| CL (1) | CL2024000834A1 (https=) |
| CO (1) | CO2024004910A2 (https=) |
| IL (1) | IL311643A (https=) |
| MX (1) | MX2024003535A (https=) |
| PE (1) | PE20241994A1 (https=) |
| TW (1) | TWI858393B (https=) |
| WO (1) | WO2023045977A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| WO2025007037A1 (en) * | 2023-06-28 | 2025-01-02 | Dragonfly Therapeutics, Inc. | Variant il-2 proteins |
| WO2025031434A1 (zh) * | 2023-08-08 | 2025-02-13 | 北京志道生物科技有限公司 | 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途 |
| WO2025140535A1 (zh) * | 2023-12-28 | 2025-07-03 | 福佑泰生物制药（新加坡）公司 | Pd-1/il-2r双特异性抗体融合蛋白及其用途和使用方法 |
| CN118373896B (zh) * | 2024-04-19 | 2025-07-29 | 上海科棋药业科技有限公司 | 抗pd-1抗体与il-2突变体的双功能融合蛋白 |
| WO2025252212A1 (zh) * | 2024-06-07 | 2025-12-11 | 福佑泰生物制药公司 | 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用 |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
| CN121293311A (zh) * | 2025-08-01 | 2026-01-09 | 合肥天港免疫药物有限公司 | Il-2变体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| IL275426B2 (en) * | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| US12280118B2 (en) * | 2017-12-27 | 2025-04-22 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| WO2020252418A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants for the treatment of cancer |
| WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
-
2022
- 2022-09-21 EP EP22872023.1A patent/EP4406965A4/en active Pending
- 2022-09-21 WO PCT/CN2022/120265 patent/WO2023045977A1/zh not_active Ceased
- 2022-09-21 TW TW111135759A patent/TWI858393B/zh active
- 2022-09-21 CN CN202280063868.9A patent/CN118119635A/zh active Pending
- 2022-09-21 CA CA3233075A patent/CA3233075A1/en active Pending
- 2022-09-21 US US18/693,453 patent/US20240391973A1/en active Pending
- 2022-09-21 JP JP2024518144A patent/JP2024534545A/ja active Pending
- 2022-09-21 IL IL311643A patent/IL311643A/en unknown
- 2022-09-21 AU AU2022350407A patent/AU2022350407B2/en active Active
- 2022-09-21 MX MX2024003535A patent/MX2024003535A/es unknown
- 2022-09-21 KR KR1020247013147A patent/KR20240082364A/ko active Pending
- 2022-09-21 PE PE2024000528A patent/PE20241994A1/es unknown
-
2024
- 2024-03-21 CL CL2024000834A patent/CL2024000834A1/es unknown
- 2024-04-18 CO CONC2024/0004910A patent/CO2024004910A2/es unknown
-
2025
- 2025-10-31 US US19/376,374 patent/US20260053898A1/en active Pending
- 2025-12-04 AU AU2025275202A patent/AU2025275202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240082364A (ko) | 2024-06-10 |
| AU2022350407A1 (en) | 2024-05-02 |
| EP4406965A1 (en) | 2024-07-31 |
| WO2023045977A1 (zh) | 2023-03-30 |
| AU2022350407B2 (en) | 2025-09-04 |
| EP4406965A4 (en) | 2025-12-17 |
| JP2024534545A (ja) | 2024-09-20 |
| CN118119635A (zh) | 2024-05-31 |
| IL311643A (en) | 2024-05-01 |
| CA3233075A1 (en) | 2023-03-30 |
| AU2025275202A1 (en) | 2026-02-19 |
| TWI858393B (zh) | 2024-10-11 |
| CL2024000834A1 (es) | 2024-09-06 |
| US20240391973A1 (en) | 2024-11-28 |
| CO2024004910A2 (es) | 2024-07-08 |
| TW202320862A (zh) | 2023-06-01 |
| MX2024003535A (es) | 2024-05-07 |
| US20260053898A1 (en) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241994A1 (es) | Proteina mutante de interleucina-2 y fusion de la misma | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| CL2025002681A1 (es) | Anticuerpos anti-ceacam5 y sus conjugados y usos | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| CL2020002144A1 (es) | Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143) | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| CY1124799T1 (el) | Παραγωγα πυριμιδινης ως ρυθμιστες υποδοχεα pge2 | |
| CL2004000900A1 (es) | Combinacion farmaceutica que comprende (i) un antagonista de la menos un receptor seleccionado de vegfr 1-3, pdgfr alfa y beta, fgfr1-3, egfr, her2, igf1r, hgfr o c-kit, y (ii) al menos un agente quimioterapeutico o terapeutico y su uso en el tratami | |
| CL2022000094A1 (es) | Anticuerpos anti-cd63, conjugados y usos de estos (divisional de la solicitud no. 202002965) | |
| CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
| BR112022027028A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso | |
| CO2022006014A2 (es) | Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| MX2024012582A (es) | Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso | |
| DOP2024000254A (es) | Macrociclos de indazol y su uso | |
| MXPA05010575A (es) | Peptacuerpo para el tratamiento del cancer. | |
| CO2023013550A2 (es) | Polipéptido de unión a gucy2c y usos del mismo |